Biogen Idec
ORG
Biogen Biogen Idec
The committee's vote is also a victory for the drug's developers, Biogen Idec and Elan, which lost substantial market value when Tysabri was withdrawn from the market, only three months after it was approved. Shares of Biogen, rose about 8 percent. Biogen executives said that if doctors rigorously monitor patients, they might detect P.M.L. early enough to stop giving Tysabri and avoid death or disability. Biogen had proposed making the registry voluntary but the F.D.A. staff objected.